CIBCX
Price
$78.25
Change
-$0.00 (-0.00%)
Updated
Aug 15 closing price
Net Assets
117.69B
SGENX
Price
$78.97
Change
+$0.13 (+0.16%)
Updated
Aug 15 closing price
Net Assets
64.23B
Interact to see
Advertisement

CIBCX vs SGENX

Header iconCIBCX vs SGENX Comparison
Open Charts CIBCX vs SGENXBanner chart's image
American Funds Capital Income Bldr C
Price$78.25
Change-$0.00 (-0.00%)
VolumeN/A
Net Assets117.69B
First Eagle Global A
Price$78.97
Change+$0.13 (+0.16%)
VolumeN/A
Net Assets64.23B
CIBCX vs SGENX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
CIBCX vs. SGENX commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CIBCX is a Buy and SGENX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CIBCX has more cash in the bank: 118B vs. SGENX (64.2B). CIBCX pays higher dividends than SGENX: CIBCX (2.29) vs SGENX (2.03). CIBCX was incepted earlier than SGENX: CIBCX (24 years) vs SGENX (55 years). CIBCX (1.34) is less costly to investors than SGENX (1.10). CIBCX is a more actively managed with annual turnover of: 56.00 vs. SGENX (9.51). CIBCX has a lower initial minimum investment than SGENX: CIBCX (250) vs SGENX (2500). SGENX annual gain was more profitable for investors over the last year : 13.82 vs. CIBCX (11.74). SGENX (45.55) and CIBCX (44.16) have equivalent 5 years return.
CIBCXSGENXCIBCX / SGENX
Total Expense Ratio1.341.10122%
Annual Report Gross Expense Ratio1.341.10122%
Fund Existence24 years55 years-
Gain YTD14.03817.83179%
Front LoadN/A5%-
Min. Initial Investment250250010%
Min. Initial Investment IRAN/AN/A-
Net Assets118B64.2B184%
Annual Yield % from dividends2.292.03113%
Returns for 1 year11.7413.8285%
Returns for 3 years27.2434.6879%
Returns for 5 years44.1645.5597%
Returns for 10 years48.7860.9980%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KPTI5.921.27
+27.31%
Karyopharm Therapeutics Inc.
CRL156.680.88
+0.56%
Charles River Laboratories International
SPKLU10.79N/A
N/A
Spark I Acquisition Corp
TRS36.77-0.20
-0.54%
TriMas Corp
ACTG3.34-0.03
-0.89%
Acacia Research Corp